CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity

被引:8
|
作者
Baumgaertner, Petra [1 ,2 ,3 ]
Schmidt, Julien [1 ,2 ,3 ]
Costa-Nunes, Carla-Marisa [1 ,2 ,3 ]
Bordry, Natacha [1 ,2 ,3 ]
Guillaume, Philippe [1 ,2 ,3 ]
Luescher, Immanuel [1 ,2 ,3 ]
Speiser, Daniel E. [1 ,2 ,3 ]
Rufer, Nathalie [1 ,2 ,3 ]
Hebeisen, Michael [1 ,2 ,3 ]
机构
[1] Lausanne Univ Hosp, Dept Oncol, Epalinges, Switzerland
[2] Univ Lausanne, Epalinges, Switzerland
[3] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, Epalinges, Switzerland
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
瑞士国家科学基金会;
关键词
cancer immunotherapy; vaccine peptide; melan-A; MART-1; NY-ESO-1; peptide-HLA binding affinity; TCR-peptide-MHC affinity; human CD8 T cells; MHC CLASS-I; BINDING-AFFINITY; ANCHOR RESIDUES; SELF-ANTIGEN; CANCER; KINETICS; COMPETITION; REVEALS; ASSAY; SUSCEPTIBILITY;
D O I
10.3389/fimmu.2022.973986
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recruitment and activation of CD8 T cells occur through specific triggering of T cell receptor (TCR) by peptide-bound human leucocyte antigen (HLA) ligands. Within the generated trimeric TCR-peptide:HLA complex, the molecular binding affinities between peptide and HLA, and between TCR and peptide:HLA both impact T cell functional outcomes. However, how their individual and combined effects modulate immunogenicity and overall T cell responsiveness has not been investigated systematically. Here, we established two panels of human tumor peptide variants differing in their affinity to HLA. For precise characterization, we developed the "blue peptide assay", an upgraded cell-based approach to measure the peptide:HLA affinity. These peptide variants were then used to investigate the cross-reactivity of tumor antigen-specific CD8 T cell clonotypes derived from blood of cancer patients after vaccination with either the native or an affinity-optimized Melan-A/MART-1 epitope, or isolated from tumor infiltrated lymph nodes (TILNs). Vaccines containing the native tumor epitope generated T cells with better functionality, and superior cross-reactivity against potential low affinity escape epitopes, as compared to T cells induced by vaccines containing an HLA affinity-optimized epitope. Comparatively, Melan-A/MART-1-specific TILN cells displayed functional and cross-reactive profiles that were heterogeneous and clonotype-dependent. Finally, we took advantage of a collection of T cells expressing affinity-optimized NY-ESO-1-specific TCRs to interrogate the individual and combined impact of peptide:HLA and TCR-pHLA affinities on overall CD8 T cell responses. We found profound and distinct effects of both biophysical parameters, with additive contributions and absence of hierarchical dominance. Altogether, the biological impact of peptide:HLA and TCR-pHLA affinities on T cell responses was carefully dissected in two antigenic systems, frequently targeted in human cancer immunotherapy. Our technology and stepwise comparison open new insights into the rational design and selection of vaccine-associated tumor-specific epitopes and highlight the functional and cross-reactivity profiles that endow T cells with best tumor control capacity.
引用
收藏
页数:17
相关论文
共 50 条
  • [2] CD8 controls T cell cross-reactivity
    Ekeruche, J.
    Wooldridge, L.
    Laugel, B.
    Clement, M.
    van den Berg, H.
    Price, D.
    Sewell, A.
    IMMUNOLOGY, 2010, 131 : 172 - 173
  • [3] CD8 Controls T Cell Cross-Reactivity
    Wooldridge, Linda
    Laugel, Bruno
    Ekeruche, Julia
    Clement, Mathew
    van den Berg, Hugo A.
    Price, David A.
    Sewell, Andrew K.
    JOURNAL OF IMMUNOLOGY, 2010, 185 (08): : 4625 - 4632
  • [4] PepSim: T-cell cross-reactivity prediction via comparison of peptide sequence and peptide-HLA structure
    Hall-Swan, Sarah
    Slone, Jared
    Rigo, Mauricio M.
    Antunes, Dinler A.
    Lizee, Gregory
    Kavraki, Lydia E.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function
    Schmid, Daphne A.
    Irving, Melita B.
    Posevitz, Vilmos
    Hebeisen, Michael
    Posevitz-Fejfar, Anita
    Sarria, J-C. Floyd
    Gomez-Eerland, Raquel
    Thome, Margot
    Schumacher, Ton N. M.
    Romero, Pedro
    Speiser, Daniel E.
    Zoete, Vincent
    Michielin, Olivier
    Rufer, Nathalie
    JOURNAL OF IMMUNOLOGY, 2010, 184 (09): : 4936 - 4946
  • [6] Impact of TCR Reactivity and HLA Phenotype on Naive CD8 T Cell Frequency in Humans
    Legoux, Francois
    Debeaupuis, Emilie
    Echasserieau, Klara
    De La Salle, Henri
    Saulquin, Xavier
    Bonneville, Marc
    JOURNAL OF IMMUNOLOGY, 2010, 184 (12): : 6731 - 6738
  • [7] Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses
    Jing, Lichen
    Laing, Kerry J.
    Dong, Lichun
    Russell, Ronnie M.
    Barlow, Russell S.
    Haas, Juergen G.
    Ramchandani, Meena S.
    Johnston, Christine
    Buus, Soren
    Redwood, Alec J.
    White, Katie D.
    Mallal, Simon A.
    Phillips, Elizabeth J.
    Posavad, Christine M.
    Wald, Anna
    Koelle, David M.
    JOURNAL OF IMMUNOLOGY, 2016, 196 (05): : 2205 - 2218
  • [8] CD8 memory T cells: cross-reactivity and heterologous immunity
    Selin, LK
    Cornberg, M
    Brehm, MA
    Kim, SK
    Calcagno, C
    Ghersi, D
    Puzone, R
    Celada, F
    Welsh, RM
    SEMINARS IN IMMUNOLOGY, 2004, 16 (05) : 335 - 347
  • [9] HLA-dependent variation in SARS-CoV-2 CD8 + T cell cross-reactivity with human coronaviruses
    Buckley, Paul R.
    Lee, Chloe H.
    Pinho, Mariana Pereira
    Babu, Rosana Ottakandathil
    Woo, Jeongmin
    Antanaviciute, Agne
    Simmons, Alison
    Ogg, Graham
    Koohy, Hashem
    IMMUNOLOGY, 2022, 166 (01) : 78 - 103
  • [10] Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation
    Holler, PD
    Kranz, DM
    IMMUNITY, 2003, 18 (02) : 255 - 264